News & Updates

Dapagliflozin improves symptoms, physical limitations in HFpEF
Dapagliflozin improves symptoms, physical limitations in HFpEF
13 Oct 2021 byRoshini Claire Anthony

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Dapagliflozin improves symptoms, physical limitations in HFpEF
13 Oct 2021
Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage
Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage
13 Oct 2021

Tocilizumab does not seem to prevent the progression of the coronavirus disease 2019 (COVID-19) to critical disease but may still be valuable in severely ill patients when used during the early inflammatory stages, a recent study has found.

Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage
13 Oct 2021
Wheat bran with RPS boosts serum SCFAs in obese people without improving health parameters
Wheat bran with RPS boosts serum SCFAs in obese people without improving health parameters
13 Oct 2021
Gene mutations may provide clues for liver cancer survival
Gene mutations may provide clues for liver cancer survival
13 Oct 2021